Illumina Inc (ILMN) - Total Liabilities
Based on the latest financial reports, Illumina Inc (ILMN) has total liabilities worth $3.56 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ILMN year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Illumina Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Illumina Inc's total liabilities have evolved over time, based on quarterly financial data.
Illumina Inc Competitors by Total Liabilities
The table below lists competitors of Illumina Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canon Inc
F:CNNA
|
Germany | €2.36 Trillion |
|
Companhia de Saneamento Básico do Estado de São Paulo - SABESP
F:SAJA
|
Germany | €61.80 Billion |
|
ideaForge Technology Limited
NSE:IDEAFORGE
|
India | £1.20 Billion |
|
Dollar Tree Inc
NASDAQ:DLTR
|
USA | $9.71 Billion |
|
Amcor PLC
NYSE:AMCR
|
USA | $25.40 Billion |
|
TECHTRONIC INDS ADR/5
F:TIB
|
Germany | €6.47 Billion |
|
Fortive Corp
NYSE:FTV
|
USA | $5.50 Billion |
|
RBC Bearings Incorporated
NYSE:RBC
|
USA | $1.88 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Illumina Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Illumina Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.89 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Illumina Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Illumina Inc (1999–2025)
The table below shows the annual total liabilities of Illumina Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.56 Billion | -9.39% |
| 2024-12-31 | $3.93 Billion | -9.99% |
| 2023-12-31 | $4.37 Billion | -22.77% |
| 2022-12-31 | $5.65 Billion | +26.27% |
| 2021-12-31 | $4.48 Billion | +54.86% |
| 2020-12-31 | $2.89 Billion | +6.96% |
| 2019-12-31 | $2.70 Billion | -11.46% |
| 2018-12-31 | $3.05 Billion | +33.44% |
| 2017-12-31 | $2.29 Billion | +16.35% |
| 2016-12-31 | $1.97 Billion | +8.84% |
| 2015-12-31 | $1.81 Billion | -3.74% |
| 2014-12-31 | $1.88 Billion | +26.32% |
| 2013-12-31 | $1.49 Billion | +19.10% |
| 2012-12-31 | $1.25 Billion | +11.32% |
| 2011-12-31 | $1.12 Billion | +74.71% |
| 2010-12-31 | $641.44 Million | +13.39% |
| 2009-12-31 | $565.69 Million | +7.04% |
| 2008-12-31 | $528.50 Million | -8.25% |
| 2007-12-31 | $576.05 Million | +981.95% |
| 2006-12-31 | $53.24 Million | +89.39% |
| 2005-12-31 | $28.11 Million | +24.15% |
| 2004-12-31 | $22.64 Million | -56.32% |
| 2003-12-31 | $51.85 Million | +3.36% |
| 2002-12-31 | $50.16 Million | +220.03% |
| 2001-12-31 | $15.67 Million | +80.31% |
| 2000-12-31 | $8.69 Million | +366.76% |
| 1999-12-31 | $1.86 Million | -- |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and … Read more